About me

Hi, I'm Juliette Sabbatani

I’m a medicinal chemist with nearly 10 years of experience in small-molecule therapeutics—advancing programs from hit identification to clinical candidate selection, while also supporting startup creation, partnerships, and strategic development.

 

At X-Chem and adMare BioInnovations, I’ve led medicinal chemistry efforts across multiple therapeutic areas and played key roles in early-stage biotech formation, due diligence, and asset evaluation. I’ve co-authored 10 patents and contributed to clinical-stage candidates through close collaboration with cross-functional teams.

 

French and Canadian, with a PhD from the University of Vienna and postdoctoral research at the Technion in Israel, I bring a strong international perspective and a deep understanding of the drug discovery landscape in both Europe and North America.

 

Curious, pragmatic, and highly adaptable, I’m known for solving complex problems and bridging science with strategy to move projects forward.


I’m always open to new ideas, partnerships, and conversations—let’s connect and see how we might work together.

Dr. Sabbatani helped to propel our drug development project to new heights.

I have learned a lot about drug development, interdisciplinary project management and IP from her during our collaborative project.

Anastassia Voronova, PhD

Associate Professor

University of Alberta

Juliette worked in my group at adMare and was a key lead on several projects.

One pain asset where she was key is now close to IND enabling studies.

A solid and dedicated medicinal chemist.

Joseph Mancini, PhD

Vice President of Research
adMare BioInnovations

Juliette collaborated on a multiparameter optimization project for a challenging target in the CNS. The project was successful in advancing to the next milestone. Her team had innovative ideas for synthesis and thoroughly analyzed data to help drive the next round of compound design.

Kristen Burford, PhD

Director of Medicinal Chemistry

Xenon Pharmaceuticals

Juliette brings creative ideas, good communication and consistent enthusiasm to collaborative efforts.  She is able to quickly digest and interpret new data to inform design hypotheses and synthesis execution. Those features enable meaningful program advancement.

Jason Crawford, PhD

EVP Drug Discovery

Gandeeva Therapeutics